Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric Adenocarcinoma
Status:
Unknown status
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
The trial aims to evaluate the efficacy and safety of adding nimotuzumab to irinotecan after
failure of first-line treatment in recurrent or metastatic gastric adenocarcinoma with
overexpression of EGFR, and search for the effective biomarkers for nimotuzumab efficacy in
gastric cancer.